you, everyone. afternoon, Raffi. And Thank good
DSUVIA. the been commercial the value further on more finding and costs recently, focused quarter, process, assets we've approval and through advancing development our for the During partner regulatory reducing high best
use the emergency month, authorization On as for targeted successfully been we're the batch report of has planned of to for the half that, front, development pleased this Niyad development preparation XXXX. of initial produced a first in
ensure Niyad commercial early to next our that launch prepared with continue planning we addition, year. for we're In potential in
this submit for end PFS-XX, an by our NDA Ephedrine next of syringe, Our planned will be prefilled the to focus year.
next multiple potential year. to bring commercial new goal forward products is throughout Our
adopted we've approach, milestones. with to approach surgery, and to by of been in specialty a able as order continue this our specifically, our sales and focus procedural people, believe grow of DSUVIA reduced with accomplish year-over-year in XXX% and this these maxillofacial. is significantly XX% suite our But distributor increase setting and important strategic ENT third We cosmetic on oral quarter a four organization to commercial cash due to only with getting accounts, increase a such year-to-date. managing even including We efficient plastic
As a an specialty large these areas. accounts from we're national in seeing interest increased result,
we're organizations active potentially partner previously discussions with our value. resourced upon larger, As to and more build in maximize disclosed, to commercial DSUVIA success DSUVIA's
We expect to quarter. the finalize this transaction
launch Aguettant, its Europe initiated partner, US in last implementing of be the DSUVIA rollout of of broad European in to smooth facilitate the will to Our physicians our in European month. and DZUVEO and launch insights DZUVEO learned markets. Aguettant commercialization from a
to move United Korea, let's circuits, first anticoagulant States. to the for circuit lot FDA nafamostat as So the device now during in dialysis. the as US for an to receiving within facilities for extracorporeal extracorporeal takes health to the its ill given the citrate FDA, of therapy. mechanism EUA the being a by the Niyad, noted an being unmet been replacement that product use renal outside for action data need, such care a use as our patients citrate for this undergoing that and body Niyad place is to we're high medical heparin the is the that that EUA. regulated alternative to developed limitations of this has significant for anti-coagulate written cGMP production given are for FDA, optimistic of from circuit like completion not anticoagulant particular, the and need feedback complexity first We unmet for is is has the need recognized an EUA stability We for about or due Based dialysis the administration. and as address our to successful indication. used plan are unmet due we're use XX% first of in widely granted We used. patients run the Yet Nafamostat for believe believe of certain equipped Niyad risks the use anticoagulants of whom such the it it Japan once South safety available. FDA citrate, many authorization and on significant could develop practical approved filter. In upon our and Niyad for submit in existing prospects product has the continuous of
as CMS an provides advantages extracorporeal processes, approval, once for salient which development previously most the toward assigns circuit, the as a the has for a work as As device ICD input submission device FDA and disclosed, several the for an assigned the we reimbursement review has breakthrough approval XX priority facilitate gaining during when will and nafamostat it's the Niyad being us regulatory well designation, this with available. FDA using Furthermore, submission already code been commercially filed. product procedural additional
study of been XXX already agency. have In full with endpoints a with conducting addition, to after we agreed plan patients registrational FDA seek the single that approval upon
As Consistent as ephedrine regional stage for circuits. excluding progress the million syringe toward product believe this late only our prefilled we markets, exceed candidates phenylephrine indication US. this from we PFS any pipeline just we And and in our anticoagulant potential is use communications, the to peak our dialysis annually assets, other the Aguettant. or products in-license priority Niyad $XXX for with for outpatient that of advance continue labeled in that NDAs stated filing could in extracorporeal to inpatient the and previous attributed we in to sales use
our Our less and and expected syringe for shelf procedures dilute safety, ephedrine NDA we year. year. candidate The our to commercialization of to with syringe or first prefilled second Aguettant's by prefilled a of on NDA convenience prefilled end the syringe, PFS-XX the is occur the label, lead this as With of Again, for having soon not of syringe the following three plan life. in Based submit next our ephedrine prefilled include shelf years. improved could advanced approval ephedrine improved the prepare ephedrine syringe. year, an prefilled the life potential is benefits of next waste, syringes an as
exceeds that to market we'll for minimal the opportunity networks. and $XXX to believe a much assets these believe stated be organizations previously, significant investment commercialization obtain with efforts are we market contracting through the expected since we hospital this and be able group of As of share million, with purchasing
the call for researchers leaders. enthusiasm handing key to Before our continued in want reiterate promise and and the medical high Raffi, market and of thought over to potential note I the DSUVIA belief
a extensive Using two ability for anesthesia, Meeting conducted in the important complex, investigated Sufentanil study last to Tablets, perform significant in surgery Plastic abstracts October discharge This surgery example, held Outpatient with large procedures Procedures in benefits allowing in procedures a announced Sublingual cohort XXX Also without of cases of example, at podium For DSUVIA, plastic of at including, presentation many that Experience Complex The October, XX general presented presentation Meeting were the Surgery a an by This DSUVIA for study XXXX. Surgery entitled, XXXX month, the and Jeffrey XXth. Plastic was we was reported DeWeese announced of we cosmetic positive Dr. Annual the results. time. made plastic through rapid Anesthesiology
found operative from at The when post had comparing Women's was versus for DSUVIA with a that following Brigham The opioids study of such DSUVIA reported Hospital significantly use first of pain versus the presentation and XXX spinal treated intravenous the intravenous lower investigator trial pain operative surgery. abstract patients post initiated patient, conducted management opioids. scores
for Defense abstract, presentation this is federal the authors setting. the abstract recent health In setting, publications as adoption DSUVIA serving in improve acute DSUVIA, of Uniformed to in second in well value the medically military, would the acute These pain practical safer nation's The management. supervised Health and from was management other for by provide the sciences patients a as University of by of for and experiencing the the our university. who Department Services continued pain endorsement of of the more Sciences, benefit pain both the which battlefield recommend those alternative
use a the Clinic surgery with Cleveland addition, DSUVIA months. in in study recently on orthopedic the patients coming publication of expected In completed
services. customer largest Department Defense. the various the is different the across This armed of points Beyond large setting, purchasing areas of has customer suite procedural many DSUVIA's
through Air recently Throughout first for their US we're you believe DoD Army, program. to have third Army. DSUVIA we the broader or orders meetings that our getting of support ensure to is In knowing I'll the financial meantime, Raffi? to the conduct and fact, on finally US opportunity that quarter, to the the US within focused other to Raffi sets, We call their make and hand US are efforts purchases branches momentum said, still the over DSUVIA's quarter outfits continues or the the Navy, army for within initiated In Force, process. troops. adoption have results. That for DSUVIA. deploying placed including acquisition kits for take the to stockpiling now continued this military, largest SKOs multiple the the past
